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Abstract. A vital function of the human placenta is to 
produce steroid hormones such as progesterone, which are 
essential for the maintenance of pregnancy and the onset of 
parturition. Although choriocarcinoma cell lines are valu-
able placental models for investigations of steroid hormone 
actions, little is known about the expression of progesterone 
receptors (PRs) in these cell lines. Therefore, in this study, the 
expression of membrane and nuclear PRs was investigated in 
cultures of fusigenic (BeWo) and non-fusigenic (JEG-3) human 
choriocarcinoma cell lines. In addition, the effects of an inducer 
of syncytialization (forskolin) on the PR expression in BeWo 
cells were assessed. Quantitative RT-PcR revealed that in fully 
syncytialized BeWo cells (treated with 50 µM forskolin for 72 h) 
there was a significant down-regulation of mPRα and up-regu-
lation of mPRβ and of the progesterone membrane component-1 
(PGRMc1) when compared with non-syncytialized BeWo cells. 
Expression of all the mPR and PGRMC1 mRNAs was signifi-
cantly lower in JEG-3 cells compared to non-syncytialized 
BeWo cells. Interestingly, expression of PR-B was unaltered 
between the two BeWo states but was significantly higher in 
JEG-3 cells. Immunofluorescence analysis revealed that mPR 
proteins are differentially expressed in these choriocarcinoma 
cell lines as well as in the human placenta. The data demon-
strate that human choriocarcinoma cell lines have a complex 
system of progesterone signalling involving multiple classes 
of PRs. The finding that syncytialization is accompanied by 
changes in the expression of these receptors may suggest that 
this process influences progesterone signalling.
Introduction
Progesterone (P4) plays a key role in the reproductive tract 
for the initiation and continuation of early pregnancy (1,2), 
and also prevents preterm labour and spontaneous abortion 
(3). Progesterone-mediated responses are complex because 
they are mediated by multiple types of progesterone receptors 
(PRs). In addition to the two well studied variants of the 
classic PRs, PR-B (116 kda) and PR-A (94 kda), new splicing 
isoforms have also been detected including PR-c (60 kda), 
PR-M (38 kda), as well as PR-S and PR-T variants that contain 
novel intronic exons (4).
Numerous research groups have shown that progesterone 
can also act at the cell surface of many target tissues and cell 
types to initiate rapid responses, via binding to membrane 
receptors (5). However, the lack of comprehensive information 
on the identity and molecular structure of membrane steroid 
receptors has prevented understanding of critical molecular 
aspects of steroid actions via this alternative mechanism and a 
more widespread appreciation of its significance (6). Recently, 
new genes exhibiting characteristics of a membrane PR (mPR) 
have been discovered. These include the family of the seven 
transmembrane domain mPRs as well as the progesterone 
receptor membrane component 1 (PGRMc1) (7). These 
receptors are structurally unrelated to the nuclear PR and 
phylogenetically distinct from the superfamily of G-protein-
coupled receptors (GPcRs) (7,8). The mPR family includes 
PAQRV (mPRγ), PAQR VI, PAQR VII (mPRα), PAQR VIII 
(mPRβ) and PAQR IX (9) and the recently described PAQR6 
(mPRδ) and PAQR9 (mPRε) (10).
Another plausible mechanism mediating the non-genomic 
actions of progesterone is through PGRMc1. This is a small 
protein (28 kDa) associated with progesterone binding (11) first 
isolated from a porcine vascular smooth muscle cell cdNA 
library (12). This protein consists of 194 amino acids (12) and 
comprises a single transmembrane domain and a cytoplasmic 
domain containing three Src homology domains that may be 
involved in the ligand-dependent signal transduction (13).
The ovaries and the fetoplacental unit are the major sources 
of progesterone (14). during human pregnancy, progesterone 
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levels rise until the third trimester and act in a paracrine or 
autocrine manner. PRs have been identified in the human 
placenta. For example, the purported cytoplasmic 60 kda PR 
isoform (PR-c) predominates in human fetal membranes and 
placenta at term (15), whereas mPRα is localised in placental 
syncytiotrophoblasts (9). PGRMc1 is also expressed in the 
human placenta primarily in syncytiotrophoblasts, smooth 
muscle cells of the placental vasculature, and in villous 
capillaries (16).
Interestingly, there is no data to date about the expres-
sion of PRs in human choriocarcinoma cell lines, which 
are used extensively as placental experimental models. 
Syncytialization is the process by which in the human 
placenta the differentiated syncytiotrophoblast layer is formed 
by the continual fusion and incorporation of new cytotropho-
blasts (17,18). Positioned at the surface of the placental villi 
the syncytiotrophoblast layer holds a crucial role in regulating 
transplacental movement of amino acids, fatty acids as well as 
glucose (19). Nutrients as well as waste products in the human 
placenta are transported across the syncytiotrophoblast layer 
by the nutrient transporters expressed on these cells (19,20). 
Variations in the activity and expression of placental nutrient 
transporters may be responsible for pregnancy complications 
such as intrauterine growth restriction IUGR (21). Moreover, 
the syncytiotrophoblast layer also has synthetic properties (22), 
including production and secretion of key, to the homeostasis 
of the pregnancy, hormones (17). In this study, we examined 
the expression of nuclear and membrane PRs including 
PGRMc1 in two human placental choriocarcinoma cell lines 
(BeWo and JEG-3). In addition, we investigated the effects of 
syncytialization on PR expression.
Materials and methods
Cell culture. BeWo and JEG-3 cell lines were purchased from 
the European collection of cell cultures (EcAcc, Salisbury, 
UK). The cells were maintained at standard culture conditions 
of 5% cO2 in air at 37˚C. BeWo cells were cultured in Ham 
F12 (Sigma-Aldrich, UK) containing 10% heat-inactivated 
fetal bovine serum (FBS), and 0.5% penicillin-streptomycin; 
whereas, JEG-3 cells were maintained in MEME (Sigma-
Aldrich) containing 10% heat-inactivated FBS, and 0.5% 
penicillin-streptomycin, 0.5% L-glutamine, 0.5% sodium 
pyruvate and 0.5% MEM non-essential amino acids.
Placental tissue. Paraffin-embedded labouring placental 
tissues were obtained from women delivering at term 
without any complications (>37 weeks of gestation, n=3). 
Ethics approval was granted by the Brunel University Ethics 
authority.
Syncytialization of BeWo cells. Forskolin (Sigma-Aldrich) 
was used as an inducer of syncytialization in BeWo cytotro-
phoblast cells. Syncytialization of BeWo cells was assessed 
with 50 and 100 µM forskolin (in dMSO) over a total period 
of 72 h, renewing forskolin treatment every 24 h. 
RNA isolation, cDNA synthesis and RT-PCR. Total ribo-
nucleic acid (RNA) was isolated using an RNA extraction kit 
(Sigma-Aldrich), according to the manufacturer's instructions. 
RNA concentration was determined by spectrophotometric 
analysis (Nanodrop; Thermo Scientific, UK) and agarose 
gel electrophoresis. RNA (500 ng) was reverse-transcribed 
into cdNA using 5 IU/µl RNase H reverse transcriptase 
(Invitrogen, UK). PCR amplification was performed using Taq 
polymerase (Invitrogen) and oligonucleotide primers as previ-
ously described (15). Twenty-eight cycles were performed 
consisting of an initial denaturing step at 94˚C for 30 sec, 
annealing at 60˚C for 1 min and elongation at 72˚C for 1 min.
Quantitative RT-PCR. Relative expression of the genes of 
interest was assessed by quantitative PcR (Q-PcR) on an 
ABI7400 instrument (Applied Biosystems) using SYBR®- 
Green-PcR reaction mixture (Sigma-Aldrich) and the primers 
described in Table I. As a negative control for all the reactions, 
distilled water was used in place of the cdNA. RNAs were 
assayed from two to three independent biological replicates. 
As a negative control, distilled water was used in place of the 
cdNA. For the quantitative PcR, the following equations were 
used: ∆Ct=Ct(gene of interest)-ct(house keeping gene); ∆∆Ct=∆Ct(sample) 
-∆Ct(calibrator) and relative quantity (RQ)=2-∆∆Ct. The RQ value 
was set up as 1 for the untreated (no supplement) BeWo cells.
Immunofluorescence analysis. Syncytialized and non-
syncitialized BeWo as well as JEG-3 cells were fixed in 4% 
paraformaldehyde for 10 min prior to washes in PBS and 
incubation with 10% bovine serum albumin (BSA) for 1 h. 
cells were incubated for 1 h with antibodies against mPRs, 
PR-B (Santa cruz Biotechnology, USA), and PGRMc1 
(provided by dr Peter Thomas) at a 1:200 dilution in 1% 
BSA/PBS. cells were then washed with PBS prior to an 
incubation with a TRITc-conjugated secondary antibody 
(Santa cruz Biotechnology) for 1 h. Slides were washed with 
PBS and mounted in Vectashield® Mounting Medium (Vector 
Laboratories) containing the dye 4,6-diamido-2-phenylindole 
(dAPI) to counterstain nuclei. Images were captured using a 
Plan Apo Neofluor 63X NA 1.25 oil objective (Zeiss) on a Zeiss 
Axiovert 200M microscope and viewed using the  AxioVision 
software. Images were taken at a set exposure time.
Protein extraction from BeWo cells. BeWo cells were cultured 
to 80% confluency, in the presence or absence of forskolin 
(50 or 100 µM up to 72 h). cells were then lysed using 200 µl 
1X Laemmli buffer (Sigma-Aldrich) and denatured for 5 min 
at 100˚C before they were cooled on ice. 
Western blotting. The samples were separated on a 10% 
SdS-polyacrylamide gel and the proteins were transferred to a 
nitrocellulose membrane. The membrane was blocked in TBS 
containing 5% dried milk powder (w/v) and 0.1% Tween-20, for 
1 h at room temperature. After three washes with TBS-0.1% 
Tween-20, the nitrocellulose membranes were incubated with 
primary antibodies against total PR, recognising both PR-A 
and PR-B (Santa cruz Biotechnology). The primary antiserum 
was used at a 1:250 dilution overnight at 4˚C. The membranes 
were washed thoroughly for 30 min with TBS-0.1% Tween, 
before incubation with the secondary HRP-conjugated immu-
noglobulin (1:2,000) for 1 h at room temperature and further 
washing for 30 min with TBS-0.1% Tween-20. Antibody 
complexes were visualised as previously described (23).
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MTT cell viability assay. The MTT solution (Sigma-Aldrich, 
Belgium) was added to the cells and incubated for 3 h and 
30 min at 37˚C. The resulting MTT formazan crystals were 
dissolved using MTT solvent, an anhydrous isopropranol 
solution, and the absorbance was measured spectrophoto-
metrically at 560 and 620 nm. This was done in order to 
get the absolute absorbance value to plot the graphs. The 
experiments were performed in triplicate wells.
PR-B staining using ImageStream analysis. BeWo cells were 
cultured to 80% confluency. Cells were then collected, and 
the pellet formed was resuspended in 1 ml PBS followed 
by  centrifugation for 5 min at 1,500 rpm. Ice-cold 50% 
methanol:50% acetone solution (1 ml) was added to the cells 
and incubated on ice for 10 min. A centrifugation step for 
5 min at 5,000 rpm followed in order to remove the fixative 
and a brief wash with PBS was performed. A further spin at 
5,000 rpm for 5 min was followed with removal of PBS. cells 
were incubated with 1 ml of 0.2% milk and 0.1% Tween-20 
in PBS and incubated at room temperature for 1 h on a roller. 
A spin at 5000 rpm for 5 min was performed to remove the 
block. The primary antibody PR-B (Santa cruz Biotechnology, 
Sc811, mouse: 1:100 dilution) was added and incubated for 
1 h at room temperature. The primary antibody was removed 
by performing a spin at 5,000 rpm for 5 min. Two washes in 
0.1% Tween-20 PBS followed prior to incubating cells with an 
anti-mouse TRITc secondary antibody (1:150 dilution) for 1 h 
at room temperature. The secondary antibody was removed, 
cells were rinsed once with 0.1% Tween-20 PBS prior to 
adding the counterstain.
Progesterone-BSA conjugated FITC staining using ImageStream 
analysis. BeWo cells were cultured to 80% confluency, cells 
were collected, and the pellet formed was resuspended in 
1 ml Ham F12 media. cells were then transferred to a 1.5 ml 
Eppendorf tube. P4 conjugated to BSA-FITc was added at 
100 nM concentration to the cells and incubated at 37˚C for 
5 min followed by centrifugation for 5 min at 1,500 rpm. 
The cells were then briefly washed with 0.1% Tween-20, PBS 
and centrifuged for 5 min at 1,500 rpm. Paraformaldehyde 
4% (0.5 ml) was added to the cells and incubated at room 
temperature for 10 min. The cells were then centifuged at 
5,000 rpm for 5 min, the fixative was carefully removed and 
the cells were briefly washed in PBS. The cells were centri-
fuged again on order to remove the PBS, fresh PBS was added 
followed by the addition of the counterstain.
Results
Syncytialization of BeWo cells. BeWo cells are fusigenic 
and when they are fully syncytialized they resemble a third 
trimester placental model; whereas, undifferentiated BeWo 
cells are similar in morphology to primary trophoblast cultures. 
In our experimental model, syncytialization was achieved 
by incubation with forskolin up to 72 h. The syncytializa-
tion model on BeWo cells was evaluated in detail, prior to 
providing a comprehensive expression map of PRs in the 
syncytialized (syncytiotrophoblasts) and non-syncytialized 
BeWo cells. We have recently provided a detailed evaluation 
of the syncytialization model of BeWo cells using different 
approaches at both the gene and protein levels. Briefly, PCNA 
Table I. Set of primers used for RT-PcR analyses.
Gene Sequence PcR product size (bp)
mPRα 5'-GcTGTTcAcTcAcATccc-3' 289
 5'-TGGTGcAAcccccAGA-3'
mPRβ 5'-GcGGcccTGGTAcTGcTGc-3' 200
 5'-cAcGGccAcccccAcA-3'
mPRγ 5'-cAGcTGTTTcAcGTGTGTGTGATccTG-3' 120
 5'-GcAcAGAAGTATGGcTccAGcTATcTGAG-3'
mPRδ 5'-ccccAAcTTcTTcAAGTccA-3' 114
 5'-cTGGAAGGAGcTGAGGAcAc-3'
PGRMc1 5'-TcTGGAcTGcAcTGTTGTccTTG-3' 290
 5'-GcAAAcAccTGTTccTATTcTG-3'
β-actin 5'-AAGAGAGGcATccTcAcccT-3' 216
 5'-TAcATGGcTGGGGTGTTGAA-3'
Syncytin-2 5'-cTccTGGccATcATGcTcTc-3' 129
 5'-GGccAccAAGATGAGAAA-3'
PR-B 5'-AGcAGTccGcTGTccTTTTcT-3' 196
 5'-ccTGAAGTTTcGGccATAccT-3'
PR-A/B 5'-TTTcGAccTccAAGGAccAT-3' 254
 5'-AGcccAcAATAcAGcTTcGAG-3'
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(proliferating cell nuclear antigen) was down-regulated in 
the treated cells when compared to the non-treated cells 
both at the mRNA and protein level. Evaluation of the cell 
membrane marker cadherin, was also performed to determine 
whether there was a decrease of the total plasma membrane in 
response to forskolin treatment. Subsequent Western blotting 
demonstrated down-regulation of cadherin protein levels in 
BeWo cells treated with forskolin (24). 
For this study, we used syncytin gene expression as an 
additional marker for syncytialization. BeWo cells treated with 
forskolin (50 or 100 µM) induced the expression of syncytin, 
a marker of syncytialization (Fig. 1A and B). An MTT assay 
was also carried out in BeWo cell cultures 48 and 72 h after 
initial plating to assess cell viability after exposing the cells to 
forskolin treatment. The principle of the MTT test is based on 
the ability of viable cells to produce formazan from the active 
cleavage of the tetrazolium salt by the functional mitochon-
dria. The MTT assay revealed that treatment of BeWo cells 
with forskolin (50 or 100 µM) for 48 h significantly inhibited 
cell growth (Fig. 1c). Similar data were evident at 72 h (data 
not shown). This was further corroborated by the appearance 
of BeWo cells using an inverted microscope, by which loss of 
the plasma membrane was evident in forskolin-treated cells, 
as they became amorphous and multinucleated (Fig. 1d).
Effect of syncytialization on of mPRs, PGRMC1 and PR 
gene expression. For this study, fully syncytialized (50 µM 
forskolin for 72 h) and non-syncytialized (untreated) BeWo 
cells were used, as well as cdNA from JEG-3 cells. Prior to 
measuring gene differences during syncytialization, the quan-
titative RT-PcR conditions were assessed. All genes were 
amplified at similar rates, giving rise to a single PCR product. 
This was evident from a single peak during the melting curve 
Figure 1. (A) Gene expression of syncytin corrected over β-actin. Lane 1, dNA ladder; lane 2, cdNA from human placenta; lane 3, cdNA from non- syn-
cytialized (untreated) BeWo cells; lane 4, from syncytialized (forskolin treated; 50 µM for 72 h) BeWo cells; and lane 5, negative control. (B) Effect of 
syncytialization on the expression of syncytin assessed by Q-PcR in treated BeWo (forskolin 50 µM for 72 h) against control BeWo (BeWo cT). (c) The 
MTT assay revealed that treatment of BeWo cells with forskolin inhibited cell growth and proliferation. (d) Microscopy revealed decreases in the overall 
content of the cell membrane in forskolin-treated BeWo cells (I) when compared with the untreated control (BeWo + dMSO; II). All experiments were 
performed in triplicate. White arrows indicate the fusion of the cell membranes.
Figure 2. (A) Q-PcR for mPRα, mPRβ, mPRγ and PGRMc1 in JEG-3 vs. 
control untreated BeWo cells (BeWo cT). (B) Effect of syncytialization on 
the expression of mPRs and PGRMc1 assessed by Q-PcR in treated BeWo 
(BeWo ST, forskolin 50 µM for 72 h) against control BeWo cells (BeWo cT). 
All experiments were performed in triplicate. 
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analysis as well as a single band when the PcR products were 
resolved on agarose gels (data not shown).
Quantitative RT-PCR revealed that there was a significant 
down-regulation of mPRα (90%), mPRδ in (99%) and a more 
modest decrease (28%) for mPRγ in forskolin-treated BeWo 
(BeWo ST) cells when compared with non-syncytialized 
BeWo (BeWo cT) cells (Fig. 2B). Interestingly, forskolin 
pre-treatment led to a significant up-regulation of mPRβ 
(127%) and PGRMc1 (77%) in syncytialized BeWo cells 
(Fig. 2B). When non-differentiated BeWo cells (fusigenic) 
were compared to JEG-3 (non-fusigenic), there was a signifi-
cantly lower expression of mPRα (58%), mPRβ (50%), mPRγ 
(38%), PGRMc1 (68%) (Fig. 2A) in JEG-3 cells, whereas 
there was no expression of mPRδ in JEG-3 cells (data not 
shown). With regards to mPRε, no apparent expression of this 
gene was detected in all cdNAs tested (data not shown). 
Semi-quantitative analysis was then used to assess the 
expression of nuclear PR-B. This approach was chosen due 
to the presence of other PR splice variants (e.g. PR-A). 
RT-PcR analysis followed by correction over β-actin 
revealed that the expression of PR-B did not varry between 
non-syncytialized and syncytialized BeWo cells (Fig. 3A). 
Interestingly, in JEG-3 there was a 4-fold increase in the 
expression of PR-B when compared to BeWo (Fig. 3A). 
We then used a specific PR-B antibody and immuno-
fluorescence analysis to assess the localisation of the nuclear 
receptor in our preparations. In JEG-3 cells, PR-B was 
localised primarily in the cytoplasm (perinuclear staining) 
with some nuclear localisation (Fig. 3c, panel I), whereas in 
non-syncytialized and syncytialized BeWo cells, PR-B was 
localised primarily in the nucleus (Fig. 3c, panels II and III). 
Western blotting was then utilised to further investigate the 
expression of PR isoforms in these cell lines. Specific bands 
~116 and 94 kda were detected in all preparations, indicative 
of the expression of the full-length PR-B and the truncated 
PR-A, respectively (Fig. 3B). The specificity of Western blot-
ting was further verified by using a PR-B specific antibody 
that produced a single immunoreactive band at 116 kda (data 
not shown).
ImageStream analysis. Following the immunofluorescence 
analysis, we used the state-of-the-art ImageStream tech-
nology that combines flow cytometry with cell imaging for 
parallel quantification and visualization of single cells. Strong 
nuclear expression of PR was evident in most of 4,448 single 
cells studied (Fig. 3d). In addition, incubation of cells with 
fluorescently conjugated P4 bound to the impermeable moiety 
BSA resulted in binding on the cell membrane of BeWo cells, 
indicative of membrane progesterone binding sites (Fig. 3E).
Cellular localisation of mPRs, PGRMC1 and PRs in JEG-3 
and BeWo cells. The protein expression and cellular locali-
sation of mPRs, and PGRMc1 was also assessed in JEG-3, 
non-syncytialized and syncytialized BeWo cells, using immu-
nofluorescence analysis. In JEG-3 cells, mPRα was expressed 
in both the plasma membrane and cytoplasm, whereas mPRβ 
Figure 3. (A) Semi-quantitative RT-PcR for PR-B corrected over β-actin, demonstrated that PR-B gene expression is not altered in forskolin-treated or 
untreated BeWo cells. (B) Western blotting of the expression of PR-A and PR-B in cell lysates from BeWo and JEG-3 cells. Total cell lysates were resolved on 
a gradient (4-20%) polyacrylamide gel. (C) Immunofluorescence analysis for PR-B in JEG-3 (I), non-syncytialized BeWo (II) and syncytialized BeWo cells 
(III). Images in (IV), (V) and (VI) are negative controls of (I), (II) and (III). (d) ImageStream analysis of PR-B in two representative BeWo cells. d1 is scatter 
cell imaging, D2 is the brightfield image of the cells, and D3 is the specific staining (red) for PR-A/B (blue arrows). (E) Binding of FITC-P4-BSA on the cell 
membrane of BeWo cells. E1 scatter cell imaging, E2 shows FITC-P4-BSA staining (white arrow; cell membrane), and E3 is the brightfield image of the cell. 
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and mPRγ showed a predominantly cytoplasmic localisation, 
PGRMc1 a strong perinuclear staining and PR-B a primarily 
cytoplasmic localisation (perinuclear staining) with some 
nuclear localisation (Fig. 4). In non-syncytialized (undifferen-
tiated) BeWo cells, mPRα, mPRβ, mPRγ and PGRMc1 were 
localised in the plasma membrane as well as in the cytoplasm 
(Fig. 4). When BeWo cells were treated with forskolin for 72 h, 
there was an evident decrease of plasma membrane followed 
by formation of polynucleated syncytia. In these cells, mPRα 
is predominantly localised in the cytoplasm (Fig. 4). 
We further assessed the localisation of mPRs in clinical 
samples. Immunofluorescence analysis of mPRs in human 
placental sections revealed a differential cellular localisation 
and distribution. mPRα was localised around syncytiotro-
phoblasts with a cytoplasmic localisation, whereas mPRβ 
was expressed both in the cytoplasm as well as on the 
plasma membrane (also around syncytiotrophoblasts) (Fig. 5). 
Interestingly, mPRγ was expressed in both syncytiotropho-
blasts and cytotrophoblasts. The expression was stronger 
around syncytiotrophoblasts, where mPRγ appeared to be 
expressed mainly on the plasma membrane (Fig. 5).
Discussion
In this study we provide a detailed map of the PR expression 
at the gene and protein levels in two human choriocarcinoma 
cell lines with different fusigenic capacities. Moreover, we 
assessed the effect of forskolin as a syncytialization agent in 
the expression of these genes.
Quantitative RT-PcR analysis revealed that in syncytialized 
BeWo cells, mPRα, mPRδ and mPRγ were down-regulated, 
whereas mPRβ and PGRMc1 were up-regulated when 
compared to non-syncytialized BeWo cells. The data indicate 
that mPRs and PGRMc1 may be implicated in the develop-
mental events leading to placental syncytialization. These 
Figure 4. Immunofluorescence analysis for mPRα, mPRβ, mPRγ, and PGRMc1 in JEG-3 cells, non-syncytialized (BeWo cT) and syncytialized cells 
(BeWo ST). 
Figure 5. Immunofluorescence analysis revealed strong cytoplasmic local-
ization for mPRα (Panel I), whereas mPRβ (Panel II), and mPRγ (Panel III) 
are distributed in the membrane (white arrows) and cytoplasm of human 
placental tissue sections. mPRγ is also expressed in cytotrophoblasts 
(dotted arrow). Panel IV is the negative control. 
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results corroborate a recent study showing that forskolin 
altered the expression of several genes during syncytialization 
of BeWo cells. Using differential display RT-PcR analysis 
and Northern blot analysis of genes such as SLPI, ELF-1α-1 
and prolyl 4-hydroxylase β were up-regulated with forskolin 
treatment (25).
When PR gene expression was compared between non-
syncytialized BeWo and JEG-3 cells, mPRα, mPRβ, mPRγ, 
and PGRMc1 mRNa levels were significantly lower in 
JEG-3 cells. No expression of mPRε was detected using 
quantitative or standard RT-PcR analyses even after 40 cycles 
of amplification. Further studies in a wider tissue repertoire 
will provide  better insight into the expression patterns of 
these genes.
The JEG-3 cell line does not have a fusigenic capacity and 
responds poorly to inducers of syncytialization. Phenotypically 
JEG-3 cells resemble the undifferentiated cytotrophoblasts, 
making it a suitable in vitro model to investigate first trimester 
placental function (26). As an additional control, the effect of 
forskolin (50 µM or 100 µM, up to 72 h) was tested on JEG-3 
cells. Treatment with forskolin did not induce the expression 
of the syncytin gene (unpublished data). These data therefore 
verify that this cell line does not fuse under stimulation of 
cAMP. Although both the JEG-3 and BeWo cell lines may 
represent a cytotrophoblastic state, there is evidence that they 
have inherent gene differences. Microarray analysis revealed 
that many transcripts were differentially expressed between 
BeWo and JEG-3 cells (27), suggesting that each cell line may 
vary in its capacity to respond to steroid hormones.
As mentioned, the human placenta expresses many PR 
isoforms (15). In our study, we provide evidence that JEG-3 
cells express the full-length PR-B as demonstrated by RT-PcR 
and Western blot analyses. Moreover, our data corroborate 
a recent study that both the PR-A and PR-B proteins are 
expressed in BeWo cells (28). The presence of multiple PR 
isoforms may be indicative of the diversity in progesterone 
responses. For example, in BeWo cells transfected with either 
PR-B or PR-A, these isoforms were found to differentially 
regulate the expression of the breast cancer resistance protein 
(29).
Immunofluorescence analysis revealed strong cytoplasmic 
staining for mPRα in both cell lines. In the human placenta 
mPRα was localised almost exclusively around syncytiotro-
phoblasts. This is in agreement with a study by Fernandes 
et al, demonstrating that mPRα expression is restricted to the 
syncytiotrophoblast at the periphery of term chorionic villi 
(9). mPRβ had a similar immunoreactivity pattern, whereas 
mPRγ was primarily expressed on the plasma membrane 
of syncytiotrophoblasts. With regards to PGRMc1, it has 
been previously shown that it is expressed in smooth muscle 
cells of the placental vasculature, villous capillaries and the 
syncytiotrophoblast (16). Interestingly, a different pattern 
of cellular localisation of mPRs and PGRMc1 was detected 
upon treatment with forskolin. For example, in non-syncytial-
ized BeWo cells, mPRα, mPRβ, mPRγ and PGRMc1 were 
observed to have a membranous and cytoplasmic localisation, 
whereas in syncytialized cells mPRα was predominantly 
localised in the cytoplasm. This could be due to the changes 
that occur at plasma membrane conent following forskolin 
treatment.
Since receptor phosphorylation can alter its expression, 
translocation, or function (30), we then studied in silico the 
potential of cyclic AMP-dependent protein kinase A (PKA) 
to directly phosphorylate the mPRs and PGRMc1 and as 
a result alter their cellular localisation. For this phospho-
specific analysis the pkaPS prediction tool (http://mendel.imp.
univie.ac.at/sat/pkaPS) was utilised to detect potential serine 
threonine (S/T) residues. The scoring function of the pkaPS 
predictor can confidently discriminate PKA phosphorylation 
sites from S/T with non-permissive sequence environments 
(sensitivity of ~96% at a specificity of ~94%) (31). No PKA 
phosphorylation sites were predicted for mPRα, mPRβ, 
mPRγ or PGRMc1, thus suggesting that activation of PKA 
by forskolin in BeWo cells cannot induce any direct post-
translational modifications of these receptors. Pretreatment of 
BeWo with specific PKA or adenylyl cyclase (AC) inhibitors 
will provide a better understanding of the extent of the 
involvement of the Ac/cAMP/PKA pathway in the cellular 
localisation of these receptors.
With regards to PR-B, in JEG-3 and non-syncytialized 
BeWo cells it appeared to have a cytoplasmic and nuclear 
localisation, whereas in forskolin-treated BeWo the localisa-
tion was primarily nuclear. This is in agreement with data 
indicating that PR-B distributes between the cytoplasm and 
the nucleus (32). Interestingly, elevation of cAMP can activate 
certain steroid receptors and augment the ligand-dependent 
activation. Rowan et al, have shown that 8-bromo-cyclic AMP 
induces phosphorylation of two sites in SRc-1 that facilitate 
ligand-independent activation of the chicken PR and are 
critical for the functional cooperation between SRc-1 and the 
cREB binding protein (33). Future studies should determine 
whether different inducers of syncytialization in BeWo cells 
can affect the activity of PRs.
To date, a few studies have provided evidence of proges-
terone-mediated actions in human choriocarcinoma cell 
lines. For example, progesterone inhibited folic acid transport 
(34) and down-regulated human organic anion transporter 4 
(hOAT4) transport activity in human placental BeWo cells (35). 
However, none of these studies clearly identifies the receptor 
mechanism via which these progesterone effects are mediated. 
Our data provide evidence for the expression of multiple PRs 
in human placental cell lines, suggestive of a higher order of 
complexity of progesterone-mediated responses. However, we 
were unable to study further protein expression and cellular 
distribution of mPRδ and mPRε, due to lack of commercially-
available antibodies. While this manuscript was in preparation, 
a study using transmission electron microscopy demonstrated 
that PRs can be present on the membrane as well as in the 
nucleus of human spermatozoa (36). Therefore, future work 
should concentrate on further dissecting the involvement of 
nuclear receptors in non-genomic responses and determine 
the cellular localisation of these receptors in human placentas 
from complicated pregnancies such as pre-eclampsia, intra-
uterine growth retardation or gestational diabetes.
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